2-(1H-benzimidazol-2-yl)-N'-hydroxy-3-(4-methoxyphenyl)propanimidamide | 1359833-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1H-benzimidazol-2-yl)-N'-hydroxy-3-(4-methoxyphenyl)propanimidamide
• CAS: 1359833-76-3
• 化学式: C₁₇H₁₈N₄O₂
• 分子量: 310.35
• InChiKey: RBIASKMRMMONJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  96.5
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease
  申请人：College of Medicine Philadelphia Health & Education Corporation d/b/a Drexel University

  公开号：US20140228355A1

  公开（公告）日：2014-08-14

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

  本发明提供了一种方法，用于抑制、抑制或预防帕金森病患者的左旋多巴诱发的运动障碍，包括向患者给予至少一种本发明化合物的药物组合物。本发明还提供了一种方法，用于抑制、抑制或预防帕金森病患者的病情，包括向患者给予至少一种本发明化合物的药物组合物。
• D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
  申请人：DREXEL UNIVERSITY

  公开号：US10543180B2

  公开（公告）日：2020-01-28

  The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.

  本发明提供了一种抑制、抑制或预防帕金森病患者左旋多巴诱发的运动障碍的方法，包括向患者施用包含至少一种本发明化合物的药物组合物的步骤。本发明进一步提供了一种抑制、抑制或预防患者帕金森病的方法，包括向患者施用包含至少一种本发明化合物的药物组合物的步骤。
• Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
  申请人：Drexel University

  公开号：US10695302B2

  公开（公告）日：2020-06-30

  The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention.

  本发明提供了一种治疗或预防有需要的受试者的注意力和/或认知障碍的方法，包括向受试者施用本发明中有用的化合物。本发明进一步提供了一种在有需要的受试者中治疗或预防与神经退行性疾病相关的痴呆症的方法，包括向受试者施用本发明中有用的化合物。
• NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE
  申请人：Philadelphia Health and Education Corporation

  公开号：EP2603215A2

  公开（公告）日：2013-06-19
• NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER
  申请人：Drexel University

  公开号：EP3062791A1

  公开（公告）日：2016-09-07